Elan has announced plans to use $1 billion from the proceeds of the sale of its stake in MS drug Tysabri to buy back its own shares.
Its shares rose on the news, gaining 4.2 per cent in Dublin at 8.30 am.
"This enables a significant portion of the unlocked value of Tysabri to be returned to shareholders directly," Elan said.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team